Innate Pharma S.A. (NASDAQ:IPHA) Q1 2026 Earnings Call Transcript

Operator: Ladies and gentlemen, thank you for joining, and welcome to the Innate Pharma First Quarter 2026 Business Update and Financial Results.

Future cancer therapy could use immunity to clean up damaged DNA by modulating AUF1

Researchers have identified a pathway that triggers an immune response in cells with defective DNA repair. In particular, the ...
RMD Open

Regulatory B cell expansion and type 1 innate lymphoid cell suppression characterise immune modulation in paediatric lupus nephritis

Objective B-cell activating factor (BAFF) is essential for B-cell survival and innate immune activation, and its ...
Frontiers

Immune endotypes and disease trajectories in autoimmune disease-associated interstitial lung disease

Interstitial lung disease (ILD) represents one of the most severe and clinically impactful manifestations of systemic autoimmune diseases, contributing ...
Tencent News

hLife | Call for Papers: Immunosenescence

Immunosenescence is the age-related decline and remodeling of the immune system, profoundly influencing susceptibility to ...
Frontiers

Immunomodulation by oligonucleotides in tissue repair, regeneration, and cancer

Oligonucleotide-based therapeutics represent a frontier in immunology, regenerative medicine, and oncology, offering unparalleled precision in modulating ...

MiNK Therapeutics to Report First Quarter 2026 Financial Results and Highlight Platform Progress Across iNKT Cell Therapy Programs

MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and immune disorders, today ...